BIIB Biogen
- 225.210
- -2.480-1.09%
- 223.000
- -2.210-0.98%
Biogen News
Biogen Has Agreed To Acquire Human Immunology Biosciences For $1.15B Upfront And Up To $650M In Potential Milestone Payments
Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases
Biogen Buys Biotech Firm HI-Bio to Boost Its Immunology Portfolio
Overnight news: Democrats submit investigation into oil giant DuPont to split into three separate companies Goldman Sachs doesn't expect the Federal Reserve to cut interest rates this year
For more global financial information, please follow the 7×24 hour real-time financial news market closing: the Federal Reserve notes highlight inflationary pressure, the Dow fell more than 200 points, the top 20 in US stock turnover on May 22: Nvidia's performance exceeded expectations, announcing that the 10% split of US WTI crude oil closed down 1.4% for the third consecutive trading day. On Wednesday, popular Chinese securities rose 1.6%, Alibaba fell 4%, Baidu fell 2.6%, European stocks fell 2.6%, European stocks fell 2.6%, European stocks fell 2.6%, European stocks fell 2.6%, European stocks fell 2.6%, European stocks fell 2.6%, European stocks fell 0.47%, European stocks fell 0.47% Macro minutes and the Federal Reserve It will People collectively support the maintenance of high profits
US Equity Markets Close Down Wednesday After Fed Minutes Raise Inflation Concerns
US equity markets ended lower Wednesday after Federal Reserve's meeting minutes raised inflation concerns. * Members of the Fed's monetary policy committee suggested earlier this month that the disinf
Sector Update: Health Care Stocks Advance Wednesday Afternoon
Health care stocks were rising Wednesday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) climbed 1
Sector Update: Health Care
Health care stocks were advancing Wednesday afternoon, with the NYSE Health Care Index rising 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.4%. The iShares Biotechnology ETF (IBB) climbe
IGM Biosciences up 40% Following Biogen HI-Bio Buy
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts.The following table summarizes their recent ratings, shedding light on the cha
Wedbush Raises Biogen Price Target to $219 From $215, Maintains Neutral Rating
Biogen (BIIB) has an average rating of outperform and price targets ranging from $200 to $350, according to analysts polled by Capital IQ. Price: 224.24, Change: -3.45, Percent Change: -1.52
Express News | Needham Reiterates Buy on Biogen, Maintains $294 Price Target
Biogen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/22/2024 29.12% Needham → $294 Reiterates Buy → Buy 05/16/2024 49.33% Truist Securities $340 → $340 Main
Biogen's Strategic Acquisition of HI-Bio and Diversification Into Orphan Drug Market Prompt 'Buy' Rating
BIIB.US to buy immunopharmaceutical developer Hi-bio for $1.8 billion
Under the terms, Baijian will pay an advance payment of $1.15 billion, as well as a potential milestone payment of up to $650 million to acquire Hi-Bio.
Biogen in up to $1.8 Billion Deal as Rare Diseases Take Center Stage
Biogen to Acquire Privately Held Human Immunology Biosciences for $1.15 Billion Upfront
By Ciara Linnane Biotech will pay up to $650 million in milestone payments on reaching certain development targets Biogen Inc. said Wednesday it's acquiring privately held Human Immunology Bioscienc
Biogen to Pay Up to $1.8 Billion for Immune Drug Developer
Express News | Biogen Inc: Acquisition of Hi-Bio Is Not Expected to Impact Biogen's Previously Issued 2024 Guidance
Express News | Biogen Inc - Biogen Expects to Finance Acquisition With Cash and May Also Draw on Its Revolving Credit Agreement
Express News | Biogen Inc: Hi-Bio's Stockholders Would Also Be Eligible for Payments of up to an Additional $650 Mln
Express News | Biogen Inc: Transaction to Include Felzartamab
Analysis
Price Target
No Data
